va Early Signs of Cardiovascular Disease in Youth With Obesity and Type 2 Diabetes By care.diabetesjournals.org Published On :: 2005-05-01 Neslihan GungorMay 1, 2005; 28:1219-1221BR Pathophysiology/Complications Full Article
va Prevalence of Hyper- and Hypoglycemia Among Inpatients With Diabetes: A national survey of 44 U.S. hospitals By care.diabetesjournals.org Published On :: 2007-02-01 Deborah J. WexlerFeb 1, 2007; 30:367-369BR Epidemiology/Health Services/Psychosocial Research Full Article
va Serum 25-Hydroxyvitamin D3 Concentrations and Prevalence of Cardiovascular Disease Among Type 2 Diabetic Patients By care.diabetesjournals.org Published On :: 2006-03-01 Massimo CigoliniMar 1, 2006; 29:722-724BR Cardiovascular and Metabolic Risk Full Article
va Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study By care.diabetesjournals.org Published On :: 2014-01-01 John M. LachinJan 1, 2014; 37:39-43DCCT/EDIC 30th Anniversary Summary Findings Full Article
va High Prevalence of Hepatitis C Virus Infection in Diabetic Patients By care.diabetesjournals.org Published On :: 1996-09-01 Rafael SimóSep 1, 1996; 19:998-1000Short Report Full Article
va Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? By care.diabetesjournals.org Published On :: 2018-01-01 Samy SuissaJan 1, 2018; 41:6-10Perspectives in Care Full Article
va Prevalence of Diabetes in Mexican Americans, Cubans, and Puerto Ricans From the Hispanic Health and Nutrition Examination Survey, 1982-1984 By care.diabetesjournals.org Published On :: 1991-07-01 Katherine M FlegalJul 1, 1991; 14:628-638Supplement 3: Diabetes in Hispanic Americans Full Article
va Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association By care.diabetesjournals.org Published On :: 2015-09-01 Caroline S. FoxSep 1, 2015; 38:1777-1803Scientific Statement Full Article
va Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum By care.diabetesjournals.org Published On :: 2018-01-01 William T. CefaluJan 1, 2018; 41:14-31Diabetes Care Expert Forum Full Article
va Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association By care.diabetesjournals.org Published On :: 2014-10-01 Sarah D. de FerrantiOct 1, 2014; 37:2843-2863Scientific Statement Full Article
va Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up By care.diabetesjournals.org Published On :: 2016-05-01 The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research GroupMay 1, 2016; 39:686-693Cardiovascular Disease and Diabetes Full Article
va Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations By care.diabetesjournals.org Published On :: 1979-03-01 T A WelbornMar 1, 1979; 2:154-160Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications Full Article
va Prevalence and Determinants of Glucose Intolerance in a Dutch Caucasian Population: The Hoorn Study By care.diabetesjournals.org Published On :: 1995-09-01 Johanna M MooySep 1, 1995; 18:1270-1273Short Report Full Article
va Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose By care.diabetesjournals.org Published On :: 1987-09-01 William L ClarkeSep 1, 1987; 10:622-628Technical Article Full Article
va Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes By care.diabetesjournals.org Published On :: 1995-02-01 Ronald KleinFeb 1, 1995; 18:258-268Kelly West Lecture 1994 Full Article
va Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study By care.diabetesjournals.org Published On :: 1979-03-01 W B KannelMar 1, 1979; 2:120-126Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications Full Article
va Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association By care.diabetesjournals.org Published On :: 2014-10-01 Sarah D. de FerrantiOct 1, 2014; 37:2843-2863Scientific Statement Full Article
va Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial By care.diabetesjournals.org Published On :: 2019-05-01 Jordi Salas-SalvadóMay 1, 2019; 42:777-788Continuing Evolution of Nutritional Therapy for Diabetes Full Article
va Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study By care.diabetesjournals.org Published On :: 2016-10-01 Khalid A. JadoonOct 1, 2016; 39:1777-1786Emerging Technologies and Therapeutics Full Article
va DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors By care.diabetesjournals.org Published On :: 2011-05-01 Dror DickerMay 1, 2011; 34:S276-S278Diabetes Treatments Full Article
va Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum By care.diabetesjournals.org Published On :: 2018-01-01 William T. CefaluJan 1, 2018; 41:14-31Diabetes Care Expert Forum Full Article
va Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE To determine if the International Hypoglycaemia Study Group (IHSG) level 2 low glucose definition can identify clinically relevant hypoglycemia in clinical trials and offer value as an end point for future trials. RESEARCH DESIGN AND METHODS A post hoc analysis was performed of the SWITCH (SWITCH 1: n = 501, type 1 diabetes; SWITCH 2: n = 721, type 2 diabetes) and DEVOTE (n = 7,637, type 2 diabetes) trials utilizing the IHSG low glucose definitions. Patients in all trials were randomized to either insulin degludec or insulin glargine 100 units/mL. In the main analysis, the following definitions were compared: 1) American Diabetes Association (ADA) 2005 (plasma glucose [PG] confirmed ≤3.9 mmol/L with symptoms); and 2) IHSG level 2 (PG confirmed <3.0 mmol/L, independent of symptoms). RESULTS In SWITCH 2, the estimated rate ratios of hypoglycemic events indicated increasing differences between treatments with decreasing PG levels until 3.0 mmol/L, following which no additional treatment differences were observed. Similar results were observed for the SWITCH 1 trial. In SWITCH 2, the IHSG level 2 definition produced a rate ratio that was lower than the ADA 2005 definition. CONCLUSIONS The IHSG level 2 definition was validated in a series of clinical trials, demonstrating its ability to discriminate between basal insulins. This definition is therefore recommended to be uniformly adopted by regulatory bodies and used in future clinical trials. Full Article
va Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans. RESEARCH DESIGN AND METHODS Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined. RESULTS Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ~30% and ~40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ~20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. CONCLUSIONS In obese humans with microvascular insulin resistance, GLP-1’s vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. Full Article
va A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Topical oxygen has been used for the treatment of chronic wounds for more than 50 years. Its effectiveness remains disputed due to the limited number of robust high-quality investigations. The aim of this study was to assess the efficacy of multimodality cyclical pressure Topical Wound Oxygen (TWO2) home care therapy in healing refractory diabetic foot ulcers (DFUs) that had failed to heal with standard of care (SOC) alone. RESEARCH DESIGN AND METHODS Patients with diabetes and chronic DFUs were randomized (double-blind) to either active TWO2 therapy or sham control therapy—both in addition to optimal SOC. The primary outcome was the percentage of ulcers in each group achieving 100% healing at 12 weeks. A group sequential design was used for the study with three predetermined analyses and hard stopping rules once 73, 146, and ultimately 220 patients completed the 12-week treatment phase. RESULTS At the first analysis point, the active TWO2 arm was found to be superior to the sham arm, with a closure rate of 41.7% compared with 13.5%. This difference in outcome produced an odds ratio (OR) of 4.57 (97.8% CI 1.19, 17.57), P = 0.010. After adjustment for University of Texas Classification (UTC) ulcer grade, the OR increased to 6.00 (97.8% CI 1.44, 24.93), P = 0.004. Cox proportional hazards modeling, also after adjustment for UTC grade, demonstrated >4.5 times the likelihood to heal DFUs over 12 weeks compared with the sham arm with a hazard ratio of 4.66 (97.8% CI 1.36, 15.98), P = 0.004. At 12 months postenrollment, 56% of active arm ulcers were closed compared with 27% of the sham arm ulcers (P = 0.013). CONCLUSIONS This sham-controlled, double-blind randomized controlled trial demonstrates that, at both 12 weeks and 12 months, adjunctive cyclical pressurized TWO2 therapy was superior in healing chronic DFUs compared with optimal SOC alone. Full Article
va Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent? By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To evaluate the respective contributions of short-term glycemic variability and mean daily glucose (MDG) concentration to the risk of hypoglycemia in type 1 diabetes. RESEARCH DESIGN AND METHODS People with type 1 diabetes (n = 100) investigated at the University Hospital of Montpellier (France) underwent continuous glucose monitoring (CGM) on two consecutive days, providing a total of 200 24-h glycemic profiles. The following parameters were computed: MDG concentration, within-day glycemic variability (coefficient of variation for glucose [%CV]), and risk of hypoglycemia (presented as the percentage of time spent below three glycemic thresholds: 3.9, 3.45, and 3.0 mmol/L). RESULTS MDG was significantly higher, and %CV significantly lower (both P < 0.001), when comparing the 24-h glycemic profiles according to whether no time or a certain duration of time was spent below the thresholds. Univariate regression analyses showed that MDG and %CV were the two explanatory variables that entered the model with the outcome variable (time spent below the thresholds). The classification and regression tree procedure indicated that the predominant predictor for hypoglycemia was %CV when the threshold was 3.0 mmol/L. In people with mean glucose ≤7.8 mmol/L, the time spent below 3.0 mmol/L was shortest (P < 0.001) when %CV was below 34%. CONCLUSIONS In type 1 diabetes, short-term glycemic variability relative to mean glucose (i.e., %CV) explains more hypoglycemia than does mean glucose alone when the glucose threshold is 3.0 mmol/L. Minimizing the risk of hypoglycemia requires a %CV below 34%. Full Article
va The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To evaluate the contemporary prevalence of diabetic peripheral neuropathy (DPN) in participants with type 1 diabetes in the T1D Exchange Clinic Registry throughout the U.S. RESEARCH DESIGN AND METHODS DPN was assessed with the Michigan Neuropathy Screening Instrument Questionnaire (MNSIQ) in adults with ≥5 years of type 1 diabetes duration. A score of ≥4 defined DPN. Associations of demographic, clinical, and laboratory factors with DPN were assessed. RESULTS Among 5,936 T1D Exchange participants (mean ± SD age 39 ± 18 years, median type 1 diabetes duration 18 years [interquartile range 11, 31], 55% female, 88% non-Hispanic white, mean glycated hemoglobin [HbA1c] 8.1 ± 1.6% [65.3 ± 17.5 mmol/mol]), DPN prevalence was 11%. Compared with those without DPN, DPN participants were older, had higher HbA1c, had longer duration of diabetes, were more likely to be female, and were less likely to have a college education and private insurance (all P < 0.001). DPN participants also were more likely to have cardiovascular disease (CVD) (P < 0.001), worse CVD risk factors of smoking (P = 0.008), hypertriglyceridemia (P = 0.002), higher BMI (P = 0.009), retinopathy (P = 0.004), reduced estimated glomerular filtration rate (P = 0.02), and Charcot neuroarthropathy (P = 0.002). There were no differences in insulin pump or continuous glucose monitor use, although DPN participants were more likely to have had severe hypoglycemia (P = 0.04) and/or diabetic ketoacidosis (P < 0.001) in the past 3 months. CONCLUSIONS The prevalence of DPN in this national cohort with type 1 diabetes is lower than in prior published reports but is reflective of current clinical care practices. These data also highlight that nonglycemic risk factors, such as CVD risk factors, severe hypoglycemia, diabetic ketoacidosis, and lower socioeconomic status, may also play a role in DPN development. Full Article
va As Governments Build Advanced Surveillance Systems to Push Borders Out, Will Travel and Migration Become Unequal for Some Groups? By www.migrationpolicy.org Published On :: Tue, 10 Mar 2020 15:13:30 -0400 As governments seek to push their borders out by amassing ever more data on travelers and migrants, their creation of increasingly complex border surveillance systems and use of risk-assessment technologies could ease mobility for some while rendering other groups immobile based on hypothetical risk profiles and decisions that are not publicly known and cannot be challenged, as this article explores. Full Article
va Una nueva política migratoria para una nueva era: Una conversación con la Secretaria de Gobernación Olga Sánchez Cordero By www.migrationpolicy.org Published On :: Thu, 28 Feb 2019 18:28:45 -0500 Durante su primera visita oficial a Washington, DC, la Secretaria de Gobierno Olga Sánchez Cordero presento un discurso público sobre la nueva política migratoria de México en el Instituto de Políticas Migratorias. Full Article
va New ADA standard, technical report available for comment by Feb. 17 By www.ada.org Published On :: Wed, 08 Jan 2020 07:00:00 -0600 The American Dental Association Standards Committee on Dental Informatics has approved two documents for circulation and comment. Full Article
va ADA Member Advantage ends two endorsements By www.ada.org Published On :: Thu, 09 Jan 2020 09:55:00 -0600 ADA Member Advantage announced Jan. 8 the end of its endorsement relationship with two companies. Full Article
va Dental schools, industry team up to create innovation centers By www.ada.org Published On :: Fri, 17 Jan 2020 10:44:00 -0600 The Center for Research & Education in Technology is encouraging dental schools to find out how to participate in its program and learn about the benefits to the school and its students. Full Article
va ADA standard on treating biofilm in waterlines available for comment By www.ada.org Published On :: Fri, 17 Jan 2020 12:35:00 -0600 The American Dental Association Standards Committee on Dental Products has approved the document for circulation and comment. Full Article
va Tufts University program provides homeless veterans with advanced dental care By www.ada.org Published On :: Tue, 28 Jan 2020 11:29:00 -0600 Service With A Smile was among 10 programs from nine universities to receive funding this year through the ADA Foundation’s E. “Bud” Tarrson Dental School Student Community Leadership Awards. Full Article
va ADA joins coalition calling for vaping regulation By www.ada.org Published On :: Thu, 06 Feb 2020 08:51:00 -0600 The American Dental Association, along with 75 organizations, is urging Congress to support legislation to regulate vaping devices and liquids in the same manner the Food and Drug Administration regulates cigarettes and other tobacco products. Full Article
va New HPI Industry Report now available By www.ada.org Published On :: Thu, 06 Feb 2020 11:26:00 -0600 Dental spending reached $136 billion in 2018 — 3.7% of all health spending — and what the ADA Health Policy Institute is calling a “historic high” in the new HPI Industry Report released Feb. 4. Full Article
va ADA technical report on age assessment by dental analysis available for review By www.ada.org Published On :: Mon, 02 Mar 2020 09:59:00 -0600 The ADA Standards Committee on Dental Informatics has approved the technical report for circulation and comment. Full Article
va Vaping bill passes House By www.ada.org Published On :: Mon, 02 Mar 2020 16:37:00 -0600 The U.S. House of Representatives Feb. 28 passed a comprehensive bill designed to address the youth tobacco epidemic. Full Article
va Private practice pays $100,000 settlement for potential HIPAA violation By www.ada.org Published On :: Fri, 06 Mar 2020 14:13:00 -0600 Ogden, Utah — The Office for Civil Rights announced March 3 that it had reached a settlement with Dr. Steven A. Porter’s medical practice to settle a potential violation of the Health Insurance Portability and Accountability Act security rule. Full Article
va Infection control webinar from ADA, OSAP available late March 20 By www.ada.org Published On :: Thu, 19 Mar 2020 11:20:00 -0500 On March 20, the ADA will release an on-demand webinar offering answers to frequently asked questions about infection control protocol and procedures related to COVID-19. Full Article
va ADA Member Advantage-endorsed companies respond to COVID-19 pandemic By www.ada.org Published On :: Wed, 25 Mar 2020 13:11:00 -0500 During these uncertain times, there is a lot of anxiety and understandably some of that comes in the form of financial worries. ADA Member Advantage-endorsed companies that provide financial services have offered information for their customers and ADA members. Full Article
va ADA Member Advantage-endorsed company, Lenovo, offers remote work and school solutions By www.ada.org Published On :: Thu, 26 Mar 2020 13:48:00 -0500 Given recent school cancellations and state orders to shelter in place, some households may be experiencing the strain of sharing family computers. ADA Member Advantage states that members are eligible for savings of up to 46% on select items from their endorsed technology provider, Lenovo, during a special sale on computers. Full Article
va ADA Member Advantage ends Chase endorsement for credit card processing By www.ada.org Published On :: Wed, 01 Apr 2020 12:02:00 -0500 ADA Member Advantage announced April 1 it ended its endorsement relationship with Chase for credit card processing. Full Article
va Code Maintenance Committee approves new codes associated with vaping, teledentistry By www.ada.org Published On :: Thu, 02 Apr 2020 10:27:00 -0500 On the heels of the ADA’s December interim policy on vaping comes a new CDT code that references counseling services about high-risk substance use including vaping. Full Article
va Harvard dental student recipient of health literacy essay contest By www.ada.org Published On :: Thu, 02 Apr 2020 10:49:00 -0500 An essay on community water fluoridation yielded a Harvard University dental student a first-place win in the annual American Dental Association’s Health Literacy in Dentistry essay contest. Full Article
va ADA will share Paycheck Protection Program information as soon as it becomes available By www.ada.org Published On :: Thu, 02 Apr 2020 16:40:00 -0500 The Association is waiting for clear guidance from the Small Business Administration on the best way to help dentists considering applying for Paycheck Protection Program 7(a) loans. Full Article
va JADA’s new CSA Corner highlights ACE Panel survey results on HPV vaccine By www.ada.org Published On :: Fri, 03 Apr 2020 14:06:00 -0500 Dentists’ comfort levels and perceived roles in discussing and administering the human papillomavirus vaccine appear to vary, according to the results of an American Dental Association Clinical Evaluators Panel survey published in The Journal of the American Dental Association. Full Article
va Webinar on Small Business Administration loans available online By www.ada.org Published On :: Fri, 10 Apr 2020 10:26:00 -0500 The ADA webinar, Small Business Administration Loans: Understanding the Options for Dentist Owners, is available online. Full Article
va SBA announces funding no longer available for Economic Injury Disaster Loans, Paycheck Protection Program By www.ada.org Published On :: Thu, 16 Apr 2020 18:59:00 -0500 The Small Business Administration said that as of April 16, the agency is unable to accept any new applications for the Paycheck Protection Program or the Economic Injury Disaster Loans due to a lack of funding. Full Article
va Dental groups seek federal approval to administer COVID-19 tests By www.ada.org Published On :: Wed, 22 Apr 2020 15:14:00 -0500 The Organized Dentistry Coalition is asking the U.S. Department of Health and Human Services to “extend federal authorization for licensed dentists to conduct Food and Drug Administration-authorized, point-of-care testing” during the COVID-19 pandemic. Full Article
va ADA Member Advantage endorses Best Card for credit card processing By www.ada.org Published On :: Fri, 01 May 2020 08:57:00 -0500 ADA Member Advantage announced May 1 that it has selected Best Card as its exclusively endorsed credit card processing solution for Association members. Full Article
